FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379524049> ?p ?o ?g. }

• W4379524049 endingPage "377" @default.
• W4379524049 startingPage "377.1" @default.
• W4379524049 abstract "Background Systemic lupus erythematosus (SLE) is an autoimmune disease, which presents an immune disorder that leads to the production of autoantibodies with potential involvement of multiple organs. Infections are one of the most frequent causes of hospitalization and death in lupus patients, and SARS-CoV-2 infection has been a global threat since March 2020. Immunization of these patients has been strongly recommended, although vaccine evaluation studies have not included this profile of patients. Objectives To evaluate the immunogenicity and safety after 2 doses of the vaccine against SARS-CoV2 in patients with SLE. Methods Subgroup of SLE patients from the prospective multicenter cohort of patients with immune-mediated diseases “SAFER” – Safety and Efficacy on COVID-19 Vaccine in Rheumatic Disease, a phase IV study. Vaccination against SARS-CoV-2 took place with vaccines approved by Brazilian regulatory bodies CoronaVac (Inactivated SARS-CoV-2 Vaccine), ChadOx-1 (AstraZeneca) and BNT162b2 (Pfizer-BioNTech) and this project followed in line with the guidelines of the National Immunization Plan in Brazil. Patients aged 18 years or older with a previous diagnosis of SLE (according to the 2019 ACR/EULAR criteria) were included. Patients were evaluated by telephone contact and in a face-to-face visit on the 28th day after each dose. Patients were followed up by means of blood collection for measurement of IgG antibody against SARS-COV-2 by chemiluminescence and disease activity assessed using SLEDAI-2K score. Results A total of 367 individuals with SLE were included, of whom 207 received 2 doses of CoronaVac, 128 received 2 doses of ChadOx-1 and 32 received 2 doses of BNT162b2. 90% of the subjects were female with a mean age of 37 years. About 42% (154) of the individuals included did not have any other associated comorbidity. 50% (182) of patients were using oral glucocorticoids and azathioprine was the most frequent immunosuppressive therapy. Regarding disease activity parameters, 38% (140) of patients had zero SLEDAI-2K at baseline and 41% (147) had zero SLEDAI-2K 28 days after the 2nd dose. Anti-DNA positivity was 30.7% (16/52) at inclusion and 32.6% (17/52) 28 days after the 2nd dose. Complement consumption was present in 18% (10/55) at inclusion and in 14.5% (8/55) 28 days after the 2nd vaccine dose. The geometric mean titers of IgG antibodies against SARS-COV-2 increased in the different vaccine groups, log 2.27 BAU/mL at inclusion and log 5.58 BAU/mL 28 days after the 2nd dose. Antibody titers after second dose varied between different vaccines, 4.96 BAU/mL CoronaVac, 6.00 BAU/mL ChadOx-1 and 7.31 BAU/mL BNT162b2 vaccine, p < 0.001. Only 3.54% (13/367) patients had covid-19 infection after the 15th day of the second dose of immunization, 9 of them having received 2 doses of CoronaVac, 4 of them of ChadOx-1 and none of them receiving BNT162b2, with p-value of 0.63. Conclusion This study suggests that vaccines against SARS-COV-2 are safe in SLE patients. Induction of immunogenicity occurred in different vaccine regimens. Only 3.5% of individuals had COVID-19 infection with no difference between the types of vaccines evaluated. Future analyzes to explore the association of the effect of immunosuppressive medication, as well as the impact of booster doses and longer follow-up on clinical outcome will be performed. References [1]Mason A, et al. Lupus, vaccinations and COVID-19: What we know now. Lupus . 2021;30(10):1541-1552. [2]Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. Ann Rheum Dis . 2021;80(10):1330-1338. [3]Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination. Arthritis Rheumatol . Published online 2021. Acknowledgements: NIL. Disclosure of Interests None Declared." @default.
• W4379524049 created "2023-06-07" @default.
• W4379524049 creator A5000536567 @default.
• W4379524049 creator A5002120049 @default.
• W4379524049 creator A5002416333 @default.
• W4379524049 creator A5003385320 @default.
• W4379524049 creator A5005074836 @default.
• W4379524049 creator A5005436584 @default.
• W4379524049 creator A5008844544 @default.
• W4379524049 creator A5008984455 @default.
• W4379524049 creator A5009353938 @default.
• W4379524049 creator A5009759975 @default.
• W4379524049 creator A5012336852 @default.
• W4379524049 creator A5013694588 @default.
• W4379524049 creator A5014777903 @default.
• W4379524049 creator A5015087474 @default.
• W4379524049 creator A5015778336 @default.
• W4379524049 creator A5017523406 @default.
• W4379524049 creator A5019063068 @default.
• W4379524049 creator A5022976564 @default.
• W4379524049 creator A5024581042 @default.
• W4379524049 creator A5031503209 @default.
• W4379524049 creator A5033272729 @default.
• W4379524049 creator A5033864763 @default.
• W4379524049 creator A5035203540 @default.
• W4379524049 creator A5035778990 @default.
• W4379524049 creator A5041542496 @default.
• W4379524049 creator A5042863197 @default.
• W4379524049 creator A5043394966 @default.
• W4379524049 creator A5043662977 @default.
• W4379524049 creator A5047171179 @default.
• W4379524049 creator A5050501084 @default.
• W4379524049 creator A5050568451 @default.
• W4379524049 creator A5052386622 @default.
• W4379524049 creator A5053799940 @default.
• W4379524049 creator A5054859400 @default.
• W4379524049 creator A5055245583 @default.
• W4379524049 creator A5058020827 @default.
• W4379524049 creator A5058929547 @default.
• W4379524049 creator A5059287765 @default.
• W4379524049 creator A5060248468 @default.
• W4379524049 creator A5060412981 @default.
• W4379524049 creator A5060476907 @default.
• W4379524049 creator A5061637871 @default.
• W4379524049 creator A5062489326 @default.
• W4379524049 creator A5062904791 @default.
• W4379524049 creator A5063367633 @default.
• W4379524049 creator A5063731373 @default.
• W4379524049 creator A5066255583 @default.
• W4379524049 creator A5070113489 @default.
• W4379524049 creator A5071110958 @default.
• W4379524049 creator A5071125674 @default.
• W4379524049 creator A5072932215 @default.
• W4379524049 creator A5073505775 @default.
• W4379524049 creator A5078560713 @default.
• W4379524049 creator A5080257414 @default.
• W4379524049 creator A5081173077 @default.
• W4379524049 creator A5081234574 @default.
• W4379524049 creator A5082221558 @default.
• W4379524049 creator A5085775206 @default.
• W4379524049 creator A5086232206 @default.
• W4379524049 creator A5086439582 @default.
• W4379524049 creator A5087498175 @default.
• W4379524049 creator A5087515773 @default.
• W4379524049 creator A5090618568 @default.
• W4379524049 creator A5029027288 @default.
• W4379524049 date "2023-05-30" @default.
• W4379524049 modified "2023-10-14" @default.
• W4379524049 title "POS0274 PROSPECTIVE EVALUATION OF THE EFFECT OF THE VACCINE AGAINST SARS-COV-2 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM SAFER STUDY" @default.
• W4379524049 doi "https://doi.org/10.1136/annrheumdis-2023-eular.5035" @default.
• W4379524049 hasPublicationYear "2023" @default.
• W4379524049 type Work @default.
• W4379524049 citedByCount "0" @default.
• W4379524049 crossrefType "journal-article" @default.
• W4379524049 hasAuthorship W4379524049A5000536567 @default.
• W4379524049 hasAuthorship W4379524049A5002120049 @default.
• W4379524049 hasAuthorship W4379524049A5002416333 @default.
• W4379524049 hasAuthorship W4379524049A5003385320 @default.
• W4379524049 hasAuthorship W4379524049A5005074836 @default.
• W4379524049 hasAuthorship W4379524049A5005436584 @default.
• W4379524049 hasAuthorship W4379524049A5008844544 @default.
• W4379524049 hasAuthorship W4379524049A5008984455 @default.
• W4379524049 hasAuthorship W4379524049A5009353938 @default.
• W4379524049 hasAuthorship W4379524049A5009759975 @default.
• W4379524049 hasAuthorship W4379524049A5012336852 @default.
• W4379524049 hasAuthorship W4379524049A5013694588 @default.
• W4379524049 hasAuthorship W4379524049A5014777903 @default.
• W4379524049 hasAuthorship W4379524049A5015087474 @default.
• W4379524049 hasAuthorship W4379524049A5015778336 @default.
• W4379524049 hasAuthorship W4379524049A5017523406 @default.
• W4379524049 hasAuthorship W4379524049A5019063068 @default.
• W4379524049 hasAuthorship W4379524049A5022976564 @default.
• W4379524049 hasAuthorship W4379524049A5024581042 @default.
• W4379524049 hasAuthorship W4379524049A5029027288 @default.
• W4379524049 hasAuthorship W4379524049A5031503209 @default.
• W4379524049 hasAuthorship W4379524049A5033272729 @default.
• W4379524049 hasAuthorship W4379524049A5033864763 @default.
• W4379524049 hasAuthorship W4379524049A5035203540 @default.

• next